Skip to main content

Advertisement

SpringerLink
Log in

Menopause hormonal therapy from the urologist’s perspective

  • Invited Commentary
  • Published:
Current Urology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comment]. JAMA 1998, 280:605–613.

    Article  PubMed  CAS  Google Scholar 

  2. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized, controlled trial [see comment]. JAMA 2002, 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  3. Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized, controlled trial [see comment]. JAMA 2004, 291:1701–1712.

    Article  PubMed  CAS  Google Scholar 

  4. Johannsson G, Burman P, Wiren L, et al.: Low-dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002, 87:2046–2052.

    Article  PubMed  CAS  Google Scholar 

  5. Shifren JL, Braunstein GD, Simon JA, et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy [see comment]. N Engl J Med 2000, 343:682–688.

    Article  PubMed  CAS  Google Scholar 

  6. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al.: Effect of estrogen plus progestin on stroke in postmenopausal women. The Women’s Health Initiative: a randomized trial [see comment]. JAMA 2003, 289:2673–2684.

    Article  PubMed  CAS  Google Scholar 

  7. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer [see comment]. Lancet 1997, 350:1047–1059 [Erratum appears in Lancet 1997, 350:1484].

    Article  Google Scholar 

  8. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 2001, 344:276–285 [Erratum appears in N Engl J Med 2001, 344:1804].

    Article  PubMed  CAS  Google Scholar 

  9. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study [see comment]. Lancet 2003, 362:419–427. [Erratum appears in Lancet 2003, 362:1160].

    Article  PubMed  CAS  Google Scholar 

  10. Beral V, Bull D, Reeves G: Endometrial cancer and hormonereplacement therapy in the Million Women Study [see comment]. Lancet 2005, 365:1543–1551.

    Article  PubMed  CAS  Google Scholar 

  11. Gilbert L, Krishnamurthy S, Tan SL, Franco EL: Estrogen replacement therapy and risk of ovarian cancer in postmenopausal women [comment]. JAMA 2002, 288:2538–2539.

    Article  PubMed  Google Scholar 

  12. Lacey JV Jr, Mink PJ, Lubin JH, et al.: Menopausal hormone replacement therapy and risk of ovarian cancer [see comment]. JAMA 2002, 288:334–341 [Erratum appears in JAMA 2002, 288:2544].

    Article  PubMed  CAS  Google Scholar 

  13. Glud E, Kjaer SK, Thomsen BL, et al.: Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004, 164:2253–2259.

    Article  PubMed  CAS  Google Scholar 

  14. Hausknecht RU, Gusberg SB: Estrogen metabolism in patients at high risk for endometrial carcinoma: II. The role of androstenedione as an estrogen precursor in postmenopausal women with endometrial carcinoma. Am J Obstet Gynecol 1973, 116:981–984.

    PubMed  CAS  Google Scholar 

  15. Arlt W, Justl HG, Callies F, et al.: Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998, 83:1928–1934.

    Article  PubMed  CAS  Google Scholar 

  16. Iosif CS, Bekassy Z: Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984, 63:257–260.

    PubMed  CAS  Google Scholar 

  17. Porter M, Penney GC, Russell D, et al.: A population-based survey of women’s experience of the menopause. Br J Obstet Gynaecol 1996, 103:1025–1028.

    Google Scholar 

  18. Barnabei VM, Grady D, Stovall DW, et al.: Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002, 100:1209–1218. [Erratum appears in Obstet Gynecol 2003, 101:619].

    Article  PubMed  CAS  Google Scholar 

  19. Eriksen PS, Rasmussen H: Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 1992, 44:137–144.

    Article  PubMed  CAS  Google Scholar 

  20. Cardozo L, Bachmann G, McClish D, et al.: Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998, 92:722–727.

    Article  PubMed  CAS  Google Scholar 

  21. North American Menopause Society: Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 Position Statement of the North American Menopause Society [see comment]. Menopause 2004, 11:589–600.

    Article  Google Scholar 

  22. Brown JS, Vittinghoff E, Kanaya AM, et al.: Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001, 98:1045–1052.

    Article  PubMed  CAS  Google Scholar 

  23. Hextall A, Hooper R, Cardozo L, et al.: Does the menopause influence the risk of bacteriuria? Int Urogynecol J Pelvic Floor Dysfunct 2001, 12:332–336.

    Article  PubMed  CAS  Google Scholar 

  24. Ouslander JG, Greendale GA, Uman G, et al.: Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J Am Geriatr Soc 2001, 49:803–807.

    Article  PubMed  CAS  Google Scholar 

  25. Hu KK, Boyko EJ, Scholes D, et al.: Risk factors for urinary tract infections in postmenopausal women. Arch Intern Med 2004, 164:989–993.

    Article  PubMed  Google Scholar 

  26. Jackson SL, Boyko EJ, Scholes D, et al.: Predictors of urinary tract infection after menopause: a prospective study. Am J Med 2004, 117:903–911.

    Article  PubMed  Google Scholar 

  27. Hooton TM: Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001, 17:259–268.

    Article  PubMed  CAS  Google Scholar 

  28. Cardozo L, Benness C, Abbott D: Low-dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998, 105:403–407.

    PubMed  CAS  Google Scholar 

  29. Eriksen B: A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999, 180:1072–1079.

    Article  PubMed  CAS  Google Scholar 

  30. Thom DH, Brown JS: Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. J Am Geriatr Soc 1998, 46:1411–1417.

    PubMed  CAS  Google Scholar 

  31. Molander U: Urinary incontinence and related urogenital symptoms in elderly women. Acta Obstet Gynecol Scand Suppl 1993, 158:1–22.

    Article  PubMed  CAS  Google Scholar 

  32. Diokno AC, Brock BM, Herzog AR, Bromberg J: Medical correlates of urinary incontinence in the elderly. Urology 1990, 36:129–138.

    Article  PubMed  CAS  Google Scholar 

  33. Jackson RA, Vittinghoff E, Kanaya AM, et al.: Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. Obstet Gynecol 2004, 104:301–307.

    PubMed  CAS  Google Scholar 

  34. Brown JS, Seeley DG, Fong J, et al.: Urinary incontinence in older women: Who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol 1996, 87:715–721.

    Article  Google Scholar 

  35. Brincat M, Moniz CJ, Studd JW, et al.: Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985, 92:256–259.

    PubMed  CAS  Google Scholar 

  36. Brincat M, Versi E, Moniz CF, et al.: Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987, 70:123–127.

    PubMed  CAS  Google Scholar 

  37. Versi E, Cardozo L, Brincat M, et al.: Correlation of urethral physiology and skin collagen in postmenopausal women. Br J Obstet Gynaecol 1988, 95:147–152.

    PubMed  CAS  Google Scholar 

  38. Bump RC, Friedman CI: Intraluminal urethral pressure measurements in the female baboon: effects of hormonal manipulation. J Urol 1986, 136:508–511.

    PubMed  CAS  Google Scholar 

  39. Jackson S, James M, Abrams P: The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 2002, 109:339–344.

    Article  PubMed  CAS  Google Scholar 

  40. Fantl JA, Bump RC, Robinson D, et al.: Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol 1996, 88:745–749.

    Google Scholar 

  41. Rufford J, Hextall A, Cardozo L, Khullar V: A doubleblind, placebo-controlled trial on the effects of 25-mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct 2003, 14:78–83.

    Article  PubMed  Google Scholar 

  42. Jackson S, Shepherd A, Brookes S, Abrams P: The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo-controlled trial [see comment]. Br J Obstet Gynaecol 1999, 106:711–718.

    PubMed  CAS  Google Scholar 

  43. Bai SW, Jung BH, Chung BC, et al.: Relationship between urinary profile of the endogenous steroids and postmenopausal women with stress urinary incontinence. Neurourol Urodyn 2003, 22:198–205.

    Article  PubMed  CAS  Google Scholar 

  44. Zhu L, Lang J, Feng R, et al.: Estrogen receptor in pelvic floor tissues in patients with stress urinary incontinence. International Int Urogynecol J Pelvic Floor Dysfunct 2004, 15:340–343.

    Google Scholar 

  45. Thom DH, van den Eeden SK, Brown JS: Evaluation of parturition and other reproductive variables as risk factors for urinary incontinence in later life. Obstet Gynecol 1997, 90:983–989.

    Article  PubMed  CAS  Google Scholar 

  46. Cardozo L, Robinson D: Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002, 60(suppl 1):64–71.

    Article  PubMed  Google Scholar 

  47. Morris E, Wilson P, Robinson J, Rymer J: Long-term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999, 106:954–959.

    PubMed  CAS  Google Scholar 

  48. Vardy MD, Lindsay R, Scotti RJ, et al.: Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003, 189:81–88.

    Article  PubMed  CAS  Google Scholar 

  49. Hendrix SL, McNeeley SG: Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann N Y Acad Sci 2001, 949:243–250.

    Article  PubMed  CAS  Google Scholar 

  50. Bachmann GA: The hypoandrogenic woman: pathophysiologic overview. Fertil Steril 2002, 77(suppl 4):S72-S76.

    Article  PubMed  Google Scholar 

  51. Sarrel PM: Androgen deficiency: menopause and estrogenrelated factors. Fertil Steril 2002, 77:S63-S67.

    Article  PubMed  Google Scholar 

  52. Bachmann G, Bancroft J, Braunstein G, et al.: Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002, 77:660–665.

    Article  PubMed  Google Scholar 

  53. Modelska K, Cummings S: Female sexual dysfunction in postmenopausal women: systematic review of placebocontrolled trials [see comment]. Am J Obstet Gynecol 2003, 188:286–293.

    Article  PubMed  CAS  Google Scholar 

  54. Miller KK, Rosner W, Lee H, et al.: Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 2004, 89:525–533.

    Article  PubMed  CAS  Google Scholar 

  55. Mosca L, Appel LJ, Benjamin EJ, et al.: Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004, 43:900–921.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, 200 First Street, SW, 55905, Rochester, MN, USA

    Deborah J. Lightner MD

Authors
  1. Deborah J. Lightner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah J. Lightner MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lightner, D.J. Menopause hormonal therapy from the urologist’s perspective. Curr Urol Rep 7, 1–3 (2006). https://doi.org/10.1007/s11934-006-0030-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-006-0030-0

Keywords

Search

Navigation